Yunnan Baiyao Group Co Ltd
SZSE:000538

Watchlist Manager
Yunnan Baiyao Group Co Ltd Logo
Yunnan Baiyao Group Co Ltd
SZSE:000538
Watchlist
Price: 58.08 CNY -2.44% Market Closed
Market Cap: 102.8B CNY
Have any thoughts about
Yunnan Baiyao Group Co Ltd?
Write Note

Yunnan Baiyao Group Co Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Yunnan Baiyao Group Co Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Investments
ÂĄ12.7B
CAGR 3-Years
120%
CAGR 5-Years
31%
CAGR 10-Years
68%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Investments
ÂĄ684.7m
CAGR 3-Years
189%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Investments
ÂĄ571.9m
CAGR 3-Years
-14%
CAGR 5-Years
-11%
CAGR 10-Years
1%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Investments
ÂĄ1.5B
CAGR 3-Years
-10%
CAGR 5-Years
53%
CAGR 10-Years
77%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Long-Term Investments
ÂĄ764.5m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Investments
ÂĄ1.6m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Yunnan Baiyao Group Co Ltd
Glance View

Market Cap
103.6B CNY
Industry
Pharmaceuticals

Yunnan Baiyao Group Co Ltd is a well-established Chinese healthcare company renowned for its pioneering products in traditional Chinese medicine, particularly in wound care and pain management. With a rich history dating back to 1902, the company originally gained fame for its unique powder that promotes blood circulation and aids in healing. Over the years, Yunnan Baiyao has evolved into a comprehensive healthcare provider, offering a diverse range of products that span over-the-counter medications, personal care items, and even high-tech medical devices. Its commitment to innovation, backed by a robust research and development framework, has positioned it as a leader in the market, appealing to both traditional and modern healthcare consumers. From an investment standpoint, Yunnan Baiyao stands out as a compelling opportunity due to its strong brand recognition and growing market share in a rapidly expanding healthcare sector. The company consistently showcases impressive financial performance, characterized by robust revenue growth and sustainable profit margins. With the rising demand for effective treatment options fueled by an aging population and increasing health awareness in China, Yunnan Baiyao is strategically positioned to capture this opportunity. As it continues to diversify its product lines and expand internationally, investors may find Yunnan Baiyao to be a promising company that embodies the principles of resilience and adaptability, traits that Warren Buffett and Charlie Munger have long advocated in value investing.

Intrinsic Value
67.17 CNY
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Yunnan Baiyao Group Co Ltd's Long-Term Investments?
Long-Term Investments
12.7B CNY

Based on the financial report for Jun 30, 2024, Yunnan Baiyao Group Co Ltd's Long-Term Investments amounts to 12.7B CNY.

What is Yunnan Baiyao Group Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
68%

Over the last year, the Long-Term Investments growth was -1%. The average annual Long-Term Investments growth rates for Yunnan Baiyao Group Co Ltd have been 120% over the past three years , 31% over the past five years , and 68% over the past ten years .

Back to Top